KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
KalVista Pharmaceuticals Presents New Data Showing Effectiveness Of Sebetralstat In Reducing Anxiety During Attacks; Supports Need For Oral On-Demand Option To Treat Attacks Earlier And More Often At The 2024 HAEi Global Angioedema Forum
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Kalvista Pharmaceuticals Inc - Sebetralstat Phase 3 Trial Meets Primary Endpoint
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
Express News | Kalvista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral on-Demand Treatment of Hereditary Angioedema
KalVista Pharmaceuticals Up Over 19%, on Pace for Largest Percent Increase Since February 2021 -- Data Talk
KalVista Pharmaceuticals Initiated at Buy by Jones Trading
JonesTrading Initiates KalVista Pharmaceuticals(KALV.US) With Buy Rating, Announces Target Price $35
Buy Rating Affirmed for KalVista Pharmaceuticals Amid Strong Phase 3 Data and Market Potential
Express News | Kalvista Pharmaceuticals Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $35
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
KalVista Appoints Brian Piekos as Chief Financial Officer
Express News | Kalvista Appoints Brian Piekos as Chief Financial Officer
Express News | Cantor Fitzgerald Reiterates Overweight on KalVista Pharma
Mispro Announces Tenth Boston Location in Cambridge, MA
Leerink Partners Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
Express News | KalVista Presented Additional Analyses Of Efficacy And Safety Of Sebetralstat From Phase 2 And Phase 3 Double-blind, Placebo-controlled Crossover Clinical Trials As Well As Interim Data From KONFIDENT-S, A Phase 3 Open-label Extension Trial